Medicine Recommendations

For adult patients treated with Pradaxa (dabigatran etexilate) when rapid reversal of its anticoagulant effects is required for emergency surgery/urgent procedures or in life-threatening or uncontrolled bleeding

Raynauds

For treating primary hypercholesterolaemia or mixed dyslipidaemia (NICE TA733)

Please refer to the LSCMMG inclisiran position statement for further information on use within Lancashire and South Cumbria

Peripheral vascular disease (NICE TA223)

NICE TA223 - Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease

Heart failure (NICE TA267), and chronic angina

NICE TA267 - Ivabradine for treating chronic heart failure 

MHRA Drug Safety Update - Ivabradine and the risk of cardiac side effects

MHRA Drug Safety Update - Ivabradine: carefully monitor for bradycardia

Treatment of POTS (postural orthostatic tachycardia syndrome)

Various indications

The colour classification is dependant on the indication. See LMWH Summary Prescribing Guide for more details. 

Treatment of patients with chronic heart failure with resistant volume overload.

Treatment of documented ventricular arrhythmias which, in the judgement of the physician, are considered as life-threatening.

Postural hypotension

Treatment of intermittent claudication in people with peripheral arterial disease (NICE TA223)

NICE TA223 - Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease

Prevention and treatment of ischaemia following subarachnoid haemorrhage

Primary and secondary prevention of cardiovascular disease

Peripheral arterial disease (NICE TA223)

NICE TA223 - Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease 

Heart failure, hypertension, diabetic nephropathy and prophylaxis of cardiovascular events

Hypertensive episodes in phaeochromocytoma

with percutaneous coronary intervention for treating acute coronary syndromes (review of technology appraisal guidance 182) (NICE TA317)

NICE TA317 Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes (review of technology appraisal guidance 182)

MHRA Drug Safety Update - Prasugrel: rare but serious hypersensitivity reactions 

As adjunctive therapy in the treatment of stable angina in patients inadequately controlled or intolerant of first-line antianginal therapies

Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and extended prevention of recurrent DVT and PE in adults

NICE TA261 - Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism

Prevention of venous thromboembolism after total hip or total knee replacement in adults (NICE TA170)

NICE TA170 - Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults